Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients

Journal of Clinical Investigation

Volumn 108, Issue 2, 2001, Pages 241-250

  Stratton, Richard ^a   Shiwen, Xu ^a   Martini, Giorgia ^a   Holmes, Alan ^a   Leask, Andrew ^b   Haberberger, Thomas ^b   Martin, George R ^b   Black, Carol M ^a   Abraham, David ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b FIBROGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; CYCLIC AMP; CYTOKINE; ICOSANOID; ILOPROST; PROSTACYCLIN RECEPTOR; PROSTACYCLIN RECEPTOR IP; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DEVICE; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN TISSUE; INFUSION; INTERSTITIAL FLUID; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN SYNTHESIS; RAYNAUD PHENOMENON; SCLERODERMA;

EID: 0034953832     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI12020     Document Type: Article

References (46)

1. Scleroderma-systemic sclerosis
2. Pathogenesis of scleroderma: Collagen
3. A strategy for determining the pathogenesis of systemic sclerosis
4. Connective tissue growth factor: A cysteine rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10
5. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis
6. Connective tissue growth factor gene expression in tissue sections from localised scleroderma, keloid, and other fibrotic skin disorders
7. Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis
8. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: Association with extent of skin sclerosis and severity of pulmonary fibrosis
9. Systemic sclerosis: A vascular perspective
10. Chemistry of stable prostacyclin analogues: Synthesis of Iloprost
11. Infusion of Iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis
12. Long term intravenous prostaglandin (epoprostinol or Iloprost) for the treatment of severe pulmonary hypertension
13. Mononuclear cell modulation of connective tissue function: Suppression of fibroblast growth by stimulation of endogenous prostaglandin production
14. The effect and interaction of bradykinin and prostaglandin on protein and collagen production by lung fibroblasts
15. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
16. Scleroderma: Classification, subsets, and pathogenesis
17. Suction blister device for separation of viable epidermis from dermis
18. The determination of lipids and proteins in suction blister fluid
19. Exchange of macromolecules between plasma and skin interstitium
20. Pharmacological and cardiovascular properties of a hydantoin derivative, BW 245C, with high affinity and selectivity for PGD2 receptors
21. Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum
22. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype
23. GR63799X: A novel prostanoid with selectivity for EP3 receptors
24. Cloning and expression of a cDNA for the human prostanoid FP receptor
25. 3H] U46619 to washed human platelets
26. Profiling of genes which are differentially expressed in mouse liver in response to adenoviral vectors and delivered genes
27. Cloning and expression of a cDNA for the human prostanoid IP receptor
28. Connective tissue growth factor mediates transforming growth factor β-induced collagen synthesis: Down-regulation by cAMP
29. Regulation of connective tissue growth factor expression by prostaglandin E2
30. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair
31. A novel transforming growth factor β response element controls the expression of the connective tissue growth factor gene
32. CTGF and smads, maintenance of scleroderma phenotype is independent of smad signaling
33. Role and interaction of connective tissue growth factor and transforming growth factor-beta in persistent fibrosis. A mouse fibrosis model
34. Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease activated receptor-1
35. Decreased collagenase expression in cultured systemic sclerosis fibroblasts
36. Concurrent down-regulation of IP prostanoid receptors and the alpha-subunit of the stimulatory guanine-nucleotide-binding protein (Gs) during prolonged exposure of neuroblastoma x glioma cells to prostanoid agonists. Quantification and functional implications
37. Cyclic AMP turnover in response to prostaglandins in intact platelets: Evidence for separate stimulatory and inhibitory prostaglandin receptors
38. Fibroblast prostaglandin E2 synthesis
39. Rapid quantification of 11 prostanoids by combined capillary column gas chromatography and negative ion chemical ionisation mass spectrometry: Application to prostanoids released from normal human embryonic lung fibroblasts W138 in a culture medium
40. Indomethacin suppresses the anti-proliferative effects of transforming growth factor-beta isoforms on fibroblast cell cultures
41. Inflammatory reaction in an experimental model of open wounds in the rat. The role of polymorphonuclear leukocytes
42. Prostaglandin and tumor necrosis factor levels in early wound inflammatory fluid: Effects of parenteral omega-3 and omega-6 fatty acid administration
43. Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts
44. 2 and to express cyclooxygenase
45. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue Iloprost in man
46. Increased levels of type I and III collagen and hyaluran in scleroderma skin